CASP1 and neurodegenerative disease: Our experimental results indicated that nordalbergin inhibited NLRP3 inflammasome activation through suppressing the cleavage of caspase-1 and IL-1β and decreasing the secretion of IL-1β, suggesting that nordalbergin has the potential to attenuate NLRP3 inflammasome-induced neuroinflammation and impede neurodegenerative disease development and progression.